ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,040.04
1.10%
US Tech 100
21,198.40
1.36%
Dow Jones
43,297.03
0.91%
Brent Oil
73.425
0.19%
Bitcoin
98,244.94
-1.06%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. IDEAYA Biosciences Inc (IDYA)

  7. IDEAYA Biosciences Inc (IDYA) News

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IDYA
DateTimeSourceHeadlineSymbolCompany
12/20/20244:53PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
12/17/20246:00AMPR Newswire (US)IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
12/16/20246:00AMPR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung CancersNASDAQ:IDYAIDEAYA Biosciences Inc
12/11/20246:00AMPR Newswire (US)IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
12/10/20246:00AMPR Newswire (US)IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerNASDAQ:IDYAIDEAYA Biosciences Inc
12/09/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 InhibitorNASDAQ:IDYAIDEAYA Biosciences Inc
12/06/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
12/02/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
11/29/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
11/18/20246:00AMPR Newswire (US)IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial OfficerNASDAQ:IDYAIDEAYA Biosciences Inc
11/12/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D DayNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202410:40AMBusiness WireBiocytogen kündigt die Nominierung des Entwicklungskandidaten IDE034 von IDEAYA, einem potenziellen ersten bispezifischen ADC (Antibody Drug Conjugate, Antikörper-Wirkstoff-Konjugat) der Klasse B7H3/PTK7 Topo-I-Nutzlast, sowie die Ausübung der...NASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202410:40AMBusiness WireBiocytogen annonce la nomination par IDEAYA du candidat IDE034, un ADC bispécifique Topo-I-Payload B7H3/PTK7, ainsi que la levée d’une optionNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/20246:00AMBusiness WireBiocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option ExerciseNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/20246:00AMPR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with BiocytogenNASDAQ:IDYAIDEAYA Biosciences Inc
11/04/20248:30AMPR Newswire (US)/C O R R E C T I O N -- IDEAYA Biosciences, Inc./NASDAQ:IDYAIDEAYA Biosciences Inc
11/04/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
11/04/20246:00AMPR Newswire (US)IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
11/01/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
10/28/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
10/25/20246:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
10/25/20246:00AMPR Newswire (US)IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024NASDAQ:IDYAIDEAYA Biosciences Inc
10/04/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
10/04/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR SymposiumNASDAQ:IDYAIDEAYA Biosciences Inc
09/27/20244:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
09/27/20244:21PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
09/27/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
09/23/20246:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
09/23/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
09/22/20249:00AMPR Newswire (US)IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:IDYA

Your Recent History

BIT
NSCIT2746104
Republic of Poland
BIT
UB5UKJ
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads